-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Systemic lupus erythematosus (SLE) is a complex of self- immune disease that can affect any organ of the body
Immune quality of life
Saphnelo (anifrolumab) is a first-class type 1 interferon receptor antibody, which has been recommended for marketing in the European Union
SLE, the most common type of lupus, is an autoimmune disease in which the immune system attacks one's own tissues, causing extensive inflammation and tissue damage in the affected organs
AstraZeneca’s Saphnelo has been shown to be effective in reducing the overall disease activity of patients with systemic lupus erythematosus
AstraZeneca’s Saphnelo has been shown to be effective in reducing the overall disease activity of patients with systemic lupus erythematosus
Compared with placebo, in these trials, more patients treated with Saphnelo had reduced overall disease activity in the entire organ system and continued to reduce oral corticosteroid (OCS) use
Ian Bruce, Professor of Rheumatology at the University of Manchester and Chairman of the Steering Committee of the Saphnelo SLE Clinical Development Project, said: “Systemic lupus erythematosus is a complex and heterogeneous disease that can adversely affect the quality of life of people
Original source:
Original source:https:// href="https://" target="_blank" rel="noopener">https:// https://
